Antibody-drug conjugates can deliver chemotherapy directly to tumors but more than 95 percent of the dose often ends up in healthy tissues, decreasing efficacy and increasing toxicity. Mythic Therapeutics FateControl technology improves the uptake of ADCs in cancerous cells while avoiding the release of their toxic payloads in healthy ones. This promises to increase efficacy of these therapies in a wide range of cancers without causing unacceptable side-effects. We spoke to Brian Fiske, co-founder, chief scientific officer of Mythic, about the challenges that have held back the benefits of ADCs, how the company’s FateControl technology addresses those, and how it is thinking of building a pipeline of ADCs across indications.
Combatting Superbugs and Emerging Viruses
How a Plant-Derived Gel Halts Bleeding in Seconds
Exploiting a Vulnerability in Cancers
Democratizing AI
A Rapid Onset Nasal Spray to Treat Mental Health Conditions
A Regenerative Medicine Company Puts Its Off-the-Shelf Vessel Replacements to the Test in Ukraine
Battling Resistance in Tumors with “Pan-Variant” Kinase Inhibitors
Treating Disease by Editing Genes in the Microbiome
Embracing the Promise of Natural Killer Cells in the Fight Against Cancer
Addressing Neurodegenerative Disease by Suppressing a Hyper Immune Response
Bringing Precision Medicine to Psychiatry
Attacking Neurodegenerative Diseases with Protein Degraders
Restoring Immune Activity While Suppressing Cancer Proliferation
A New Model for Preventing Life-Threatening Blood Clots
The Race to Live Forever
A Model for Moving from Breakthrough to Blockbuster
Building the Next-Generation of Cell and Gene Therapies
Building Small Molecule Drugs that Are Superior to Biologics
A New Class of Cancer Therapies Targets Solid Tumors with a Dual Action
A Pursuit of Off-The-Shelf CAR-T Therapies
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Stuff To Blow Your Mind
Unexplainable
Ground Truths